Tag: Headtohead

For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atopic dermatitis (AD). In the LEVEL UP trial testing patients age 12 and older with moderate-to-severe AD who had an inadequate response to systemic therapy, 20% of […]